Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes

Hepatology Research

Volumn 24, Issue 3, 2002, Pages 228-235

  Hara, Koji ^a   Ikeda, Masanori ^a   Saito, Satoru ^a   Matsumoto, Shuhei ^a   Numata, Kazushi ^a,b   Kato, Nobuyuki ^c   Tanaka, Katsuaki ^d   Sekihara, Hisahiko ^a  

^a Third Department of Internal Medicine   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Anti viral effect; Hepatitis B virus; Hepatocytes; Infection; Lactoferrin; Nested PCR

Indexed keywords

ALBUMIN; CARRIER PROTEIN; CASEIN; LACTOFERRIN; MILK PROTEIN; TRANSFERRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL CULTURE; PRIORITY JOURNAL; PROTEIN INTERACTION;

EID: 0036846498     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00088-8     Document Type: Article

References (43)

1. Vogel CL, Anthony PP, Sadikali F, Barker LF, Peterson MR. Hepatitis-associated antigen and antibody in hepatocellular carcinoma: results of a continuing study. J Natl Cancer Inst 1972;48:1583-8.
2. Obata H, Hayashi N, Motoike Y, et al. A prospective study on the development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection. Int J Cancer 1980;25:741-7.
3. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol 1978;24:40-69.
4. Summers J, O'Connell A, Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci USA 1975;72:4597-601.
5. Robinson WS. The genome of hepatitis B virus. Annu Rev Microbiol 1977;31:357-.
6. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. Coli. Nature 1979;281:646-50.
7. Colacino JM, Staschke KA. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res 1998;50:259-322.
8. Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999;29:939-45.
9. Hasegawa K, Motsuchi W, Tanaka S, Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn Med Sci Biol 1995;47:73-85.
10. Bullen JJ, Rogers HJ, Griffiths E. Role of iron in bacterial infection. Curr Top Microbiol Immunol 1987;80:1-35.
11. Cohen MS, Britigan BE, French M, Bean K. Preliminary observations on lactoferrin secretion in human vaginal mucus: variation during the menstrual cycle, evidence of hormonal regulation, and implication for infection with Neisseria gonorrhoeae. Am J Obstet Gynecol 1987;157:1122-5.
12. Masson PL, Heremans LF, Dive CH. An iron-binding protein common to many external secretions. Clin Chim Acta 1966;14:735-9.
13. Lonnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr 1995;15:93-110.
14. Spik G, Strecker G, Fournet B, et al. Primary structure of the glycans from human lactoferrin. Eur J Biochem 1982;121:413-9.
15. Yamauchi K, Tomita M, Giehl TJ, Elison RT, III. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993;61:719-28.
16. Kirkpatrick CH, Green I, Rich RR, Schade AL. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host defense mechanisms in chronic mucocutaneous Candidasis. J Infect Dis 1971;124:539-44.
17. Harmsen MC, Swart PJ, deBethune MP, et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995;172:380-8.
18. Ikeda M, Sugiyama K, Tanaka T, et al. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 1998;245:549-53.
19. Noguchi M, Hirohashi S. Cell lines from non-neoplastic liver and hepatocellular carcinoma tissue from a single patient. In vitro cell. Dev Biol Anim 1996;32:135-7.
20. Kato N, Ikeda M, Mizutani T, et al. Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes. Jpn J Cancer Res 1996;87:787-92.
21. Ikeda M, Kato N, Mizutani T, Sugiyama K, Tanaka K, Shimotohno K. Analysis of the cell tropism of HCV by using in vivo HCV-infected human lymphocytes and hepatocytes. J Hepatol 1997;27:445-54.
22. Kato N, Sekiya H, Ootsuyama Y, et al. Humoral immune response to hypervariable region I of the putatice envelope glycoprotein (gp70) of hepatitis C virus. J Vilol 1993;67:3923-30.
23. Mizutani T, Ikeda M, Saito S, Sugiyama K, Shimotohno K, Kato N. Single-step reverse transcription-polymerase chain reaction for the detection of hepatitis C virus RNA. Microbiol Immunol 1998;42:544-53.
24. Nozaki A, Naganuma A, Nakamura T, Tanaka K, Sekihara H, Kato N. A reliable internally controlled RT-Nested PCR Method for the detection of hepatitis C virus RNA. Acta Med (Okayama) 2000;54:253-7.
25. Mizutani T, Kato N, Ikeda M, Sugiyama K, Shimotono K. Long-term human T cell culture system supporting hepatitis C virus replication. Biochem Biophys Res Commun 1996;277:822-6.
26. Zhang GH, Mann DM, Tsai CM. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun 1999;67:1353-8.
27. Appelmelk BJ, An YQ, Geerts M, et al. Lactoferrin is a lipid A-binding protein. Infect Immun 1994;62:2628-32.
28. Cole AM, Dewan P, Ganz T. Innate antimicrobial activity of nasal secretions. Infect Immun 1999;67:3267-75.
29. Schibli DJ, Hwang PM, Vogel HJ. The structure of the antimicrobial active center of lactoferricin B bound to sodium dodecyl sulfate micelles. FEBS Lett 1999;446:213-7.
30. Kuipers ME, de Vries FIG, Eikelboom MC, Meijer DK, Swart PJ. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isoletes. Antimicrob Agents Chemother 1999;43:2635-41.
31. Yi M, Kaneko S, Yu DY, Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J Virol 1997;71:5997-6002.
32. Mazurier J, Legrand D, Hu WL, Montreuil J, Spik G. Expression of human lactotransferrin receptors in phyto-hemagglutinin-stimulated human peripheral blood lymphocytes. Isolation of the receptors by antiligand-affinity chromatography. Eur J Biochem 1989;179:481-7.
33. van Dijk MC, Ziere GJ, van Berkel TJ. Characterization of the chylomicron-remnant-recognition sites on parenchymal and Kupffer cells of rat liver. Selective inhibition of parenchymal cell recognition by lactoferrin. Eur J Biochem 1992;205:775-84.
34. Kajikawa M, Ohta T, Takase M, Kawase K, Shimamura S, Matsuda I. Lactoferrin inhibits cholesterol accumulation in macrophages mediated by acetylated or oxidized low-density lipoproteins. Biochim Biophys Acta 1994;1213:82-90.
35. Damiens E, El Tazidi I, Mazurier J, et al. Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. Eur J Cell Biol 1998;77:344-51.
36. Shimazaki K, Tazume T, Uji K, et al. Properties of a heparin-binding peptide derived from bovine lactoferrin. J Dairy Sci 1998;81:2841-9.
37. McAbee DD, Bennatt DJ, Ling YY. Identification and analysis of a CA (2+) -dependent lactoferrin receptor in rat river. Lactoferrin binds to the asialoglycoprotein receptor in a galactose-independent manner. Adv Exp Med Biol 1998;443:113-21.
38. Treichel U, Meyer zumBuschenfelde KH, Dienes HP, Gerken G. Receptor-mediated entry of hepatitis B virus particles into liver cells. Arch Virol 1997;142:493-8.
39. Brock J. Lactoferrin: a multifunctional immunoregulatory protein. Immunol Today 1995;16:417-9.
40. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidial domain of lactoferrin. Biochim Biophys Acta 1992;1121:130-6.
41. Mann DM, Romm E, Migliorini M. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J Biol Chem 1994;269:23661-7.
42. Atkins GJ, Qiao M, Coombe DR, Gowans EJ, Ashman LK. Hepatitis B virus binding to leucocyte plasma membranes utilizes a different region of the preS1 domain to the hepatocyte receptor binding site and does dot require receptors for opsonins. Immunol Cell Biol 1997;75:259-66.
43. Tanaka K, Ikeda M, Nozaki A, Kato N, Tsuda H, Saito S, Sekihara H. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn J Cancer Res 1999;90:367-71.